EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mental Disorders and Quality of Life in Patients With Pulmonary Arterial Hypertension Treated With Sotatercept

Jan Fuge, Karen M Olsson iD, Kira Remmert, Britta Stapel, Jan C Kamp iD, Da-Hee Park iD, Marius M Hoeper, Lotta Winter, Kai G Kahl

Pulmonary Circulation · 2026-04 · 16 (2)

DOI: 10.1002/pul2.70324 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pulmonary Circulation, online erschienen am 21.05.2026. Verfasst von Jan Fuge und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine and Infectious Diseases Hannover Medical School Hannover Germany. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sotatercept has recently expanded treatment options for pulmonary arterial hypertension (PAH), but its mental health and quality‐of‐life impact is not well characterized. We assessed psychiatric diagnoses and patient‐reported outcomes in PAH patients treated with sotatercept within the clinical trial program. PAH Patients previously assessed for psychiatric disorders and quality of life were re‐evaluated after ≥ 6 months of sotatercept exposure. A senior psychiatrist performed a Structured Clinical Interview for DSM‐5, and participants completed validated questionnaires assessing anxiety/depression (HADS), metacognitive beliefs (MCQ‐30), quality of life (WHOQOL‐BREF), and PAH‐related symptoms/impacts (PAH‐SYMPACT™), alongside items capturing patient experiences during therapy. Twenty patients (85% female; median age 46 years) were included. Hemodynamics, biomarkers, and 6‐min walk distance improved. The prevalence of at least one current psychiatric disorder remained high and largely unchanged from baseline to follow‐up (50% to 45%). Major depressive disorder remained stable (25%), whereas adjustment disorder newly occurred in 25% of patients. HADS and MCQ‐30 scores did not change. WHOQOL‐BREF global scores increased modestly, but the mental health domain declined substantially (69.6 ± 13.3 to 48.1 ± 15.5, p = 0.001). PAH‐SYMPACT™ indicated low symptom burden at follow‐up. Many patients reported increased optimism and plans to travel or return to work, while some expressed concerns about finances and social security. While sotatercept treatment led to clinical improvements in PAH patients, the prevalence of mental disorders remained high with an increased prevalence in adjustment disorder. These findings support routine mental health assessment and targeted psychosocial support when initiating life‐changing PAH therapies.

Schlagwörter

Stichwörter der Autor:innen

metacognitionpatient‐reported outcomespsychosocial adaptationstructured clinical interview for DSM‐5 (SCID)

Autor:innen und Institutionen

  • Department of Respiratory Medicine and Infectious Diseases Hannover Medical School Hannover Germany.
  • Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL) Hannover Germany.
  • Department of Psychiatry, Social Psychiatry and Psychotherapy Hannover Medical School Hannover Germany.

ORCID-Profile: Karen M Olsson, Jan C Kamp, Da-Hee Park

Zitieren

APA

Fuge, J., Olsson, K. M., Remmert, K., Stapel, B., Kamp, J. C., Park, D. H., Hoeper, M. M., Winter, L., & Kahl, K. G. (2026). Mental Disorders and Quality of Life in Patients With Pulmonary Arterial Hypertension Treated With Sotatercept. Pulmonary Circulation, 16(2). https://doi.org/10.1002/pul2.70324

Vancouver

Fuge J, Olsson KM, Remmert K, Stapel B, Kamp JC, Park DH, et al. Mental Disorders and Quality of Life in Patients With Pulmonary Arterial Hypertension Treated With Sotatercept. Pulmonary Circulation. 2026;16(2). doi:10.1002/pul2.70324

BibTeX
@article{Fuge2026,
  author = {Fuge, Jan and Olsson, Karen M and Remmert, Kira and Stapel, Britta and Kamp, Jan C and Park, Da-Hee and Hoeper, Marius M and Winter, Lotta and Kahl, Kai G},
  title = {Mental Disorders and Quality of Life in Patients With Pulmonary Arterial Hypertension Treated With Sotatercept},
  journal = {Pulmonary Circulation},
  year = {2026},
  volume = {16},
  number = {2},
  doi = {10.1002/pul2.70324}
}
Kostenlos starten →